Advertisement
BRKR vs MEDP
Which Stock Would AI Choose? Bruker Corporation (BRKR) vs. Medpace Holdings (MEDP) Stock Comparison
Key Takeaways
- BRKR (Bruker Corporation) is a scientific-instruments and diagnostics maker facing organic revenue declines and margin pressure, offset by firming order trends in semiconductor metrology.
- MEDP (Medpace Holdings) is a clinical research organization (CRO) posting double-digit revenue growth and a rebound in net bookings after a period of elevated cancellations.
- Bruker's growth is cyclical and hardware-driven; Medpace's is services-driven and tied to biopharma research-and-development budgets.
- Medpace recently raised its 2026 outlook and completed a large share buyback, while Bruker trimmed its full-year revenue guidance.
- Both names carry distinct risks: margin and funding headwinds for Bruker, and project-cancellation and client-concentration risk for Medpace.
Introduction
Investors comparing BRKR and MEDP are weighing two very different plays on the life-sciences economy. Bruker Corporation sells high-performance scientific instruments and diagnostics, while Medpace Holdings provides outsourced clinical-trial management services. This stock comparison is most relevant to traders and investors seeking exposure to healthcare-adjacent growth but deciding between a cyclical equipment franchise and a recurring, services-oriented CRO. Understanding their relative performance, market positioning, and risk profiles helps clarify which business may be better suited to current market conditions.
BRKR Overview and Recent Performance
Bruker Corporation (BRKR) designs scientific instruments and analytical solutions for life-science research, specialty diagnostics, microscopy, and next-generation semiconductor metrology. Its business spans segments such as BioSpin, CALID, and Nano, serving academic, biopharma, and industrial customers.
Recent market activity has been volatile. In its first-quarter 2026 report, Bruker beat adjusted earnings-per-share (EPS) estimates, yet adjusted EPS still fell year over year and organic revenue declined, with gross margin contracting. Management pointed to volume and mix, foreign exchange, and tariffs as headwinds. The company reaffirmed its 2026 outlook at that time, citing a BSI book-to-bill ratio above 1.0x for a third straight quarter. However, a subsequent second-quarter report revealed a revenue shortfall, and Bruker trimmed its full-year revenue guidance while reiterating its EPS target. U.S. academic and government funding softness and delivery timing in semiconductor metrology weighed on results.
Despite these challenges, sentiment has partially recovered in recent weeks, supported by durable demand linked to artificial-intelligence (AI) semiconductor manufacturing, spatial biology product launches, and cost-savings initiatives. Analyst price targets remain wide-ranging, reflecting uncertainty around the pace of recovery.
MEDP Overview and Recent Performance
Medpace Holdings (MEDP) is a contract research organization that provides clinical development services for pharmaceutical, biotechnology, and medical-device companies. It manages clinical trials across therapeutic areas, with a focus on small and mid-sized biotech sponsors.
Medpace's recent performance has been strong on the top line but uneven on bookings. First-quarter 2026 revenue rose more than 25% year over year, yet elevated project cancellations pushed the net book-to-bill ratio below 1.0x, pressuring the stock. The narrative shifted in the second quarter, when revenue grew 17.2% year over year and net new business awards reached a record level, lifting the book-to-bill ratio to 1.13x. Management also raised its 2026 net-income guidance and completed a substantial share repurchase that retired a meaningful portion of shares outstanding, amplifying EPS.
Sentiment has improved in recent weeks as cancellations moderated and oncology demand re-accelerated, though client concentration and the inherently unpredictable nature of trial cancellations remain key watchpoints.
Trending AI Robots
Tickeron operates a marketplace of hundreds of AI trading bots that monitor and trade thousands of different tickers, each with its own strategy, timeframe, performance statistics, and universe of securities. Because not every bot fits every market regime, Tickeron curates a Trending AI Robots section that highlights a select group—roughly two dozen standout bots chosen from a pool of more than 300—deemed most suitable for current conditions. Featured bots span themes such as semiconductors, technology, industrials, and healthcare/biotech, and are displayed alongside metrics including realized return, win rate, profit factor, average trade duration, and profit-to-drawdown ratio. Explore the Trending AI Robots page to see which strategies are currently leading the market.
Head-to-Head Comparison
The two companies operate at opposite ends of the life-sciences value chain. Bruker is a capital-equipment manufacturer whose revenue depends on instrument purchases—a cyclical, order-driven model sensitive to academic funding, foreign exchange, and semiconductor capital spending. Medpace is a services business with a multi-billion-dollar backlog that converts to revenue over time, offering greater visibility but exposing it to cancellation and client-concentration risk.
On growth, Medpace has delivered consistently double-digit revenue expansion, while Bruker has struggled with organic declines and margin contraction. On momentum, Medpace's second-quarter bookings rebound and raised guidance stand in contrast to Bruker's trimmed revenue outlook. Risk profiles also differ: Bruker faces macro, currency, and funding headwinds, whereas Medpace faces trial-cancellation volatility and a top-10 customer base accounting for roughly 40% of revenue.
Sector exposure further separates them. Bruker is increasingly levered to AI-driven semiconductor metrology and advanced packaging demand, while Medpace is tied to biopharma R&D (research and development) budgets and the pace of biotech outsourcing. Both carry meaningful insider-selling signals, a factor some traders monitor closely.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely lean toward MEDP in the current environment. Medpace demonstrates stronger revenue growth momentum, a recovering book-to-bill ratio, a raised earnings outlook, and an active capital-return program—all characteristics associated with more consistent trend strength and relative positioning. Bruker's improving order book and AI-semiconductor exposure are genuine positives, but its organic revenue decline and margin pressure introduce greater near-term uncertainty. The verdict is probabilistic rather than definitive: cancellation trends at Medpace and funding dynamics at Bruker could shift the balance. Traders may find value in monitoring both names through AI-driven tools that adapt to changing market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BRKR is a Hold and MEDP is a Hold.
Momentum Indicator for BRKR turns positive, indicating new upward trend
BRKR saw its Momentum Indicator move above the 0 level on October 26, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned positive. In 72 of the 95 cases, the stock moved higher in the following days. The odds of a move higher are at 76%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for BRKR just turned positive on October 27, 2026. Looking at past instances where BRKR's MACD turned positive, the stock continued to rise in 34 of 45 cases over the following month. The odds of a continued upward trend are 76%.
Following a +6.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where BRKR advanced for three days, in 198 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 52 of 64 cases where BRKR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.
BRKR moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BRKR crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BRKR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
BRKR broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.651) is normal, around the industry mean (4.201). P/E Ratio (-81.529) is within average values for comparable stocks, (1.335). Projected Growth (PEG Ratio) (1.070) is also within normal values, averaging (11.052). Dividend Yield (0.004) settles around the average of (0.010) among similar stocks. P/S Ratio (2.634) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. BRKR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BRKR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
MEDP's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for MEDP turned positive on October 15, 2026. Looking at past instances where MEDP's MACD turned positive, the stock continued to rise in 42 of 51 cases over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on MEDP as a result. In 76 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
MEDP moved above its 50-day moving average on October 05, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where MEDP advanced for three days, in 237 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 192 of 255 cases where MEDP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
Bearish Trend Analysis
The 10-day RSI Indicator for MEDP moved out of overbought territory on October 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 25 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 69%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MEDP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
MEDP broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 19 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. MEDP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (41.946) is normal, around the industry mean (67.473). P/E Ratio (37.580) is within average values for comparable stocks, (2.957). Projected Growth (PEG Ratio) (2.929) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.390) is also within normal values, averaging (9.775).
BRKR | MEDP | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 27 | 38 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 83 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 19 | |
SMR RATING 1..100 | 92 | 11 | |
PRICE GROWTH RATING 1..100 | 39 | 38 | |
P/E GROWTH RATING 1..100 | 99 | 54 | |
SEASONALITY SCORE 1..100 | 90 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BRKR's Valuation (8) in the Medical Specialties industry is significantly better than the same rating for MEDP (83) in the Miscellaneous Commercial Services industry. This means that BRKR’s stock grew significantly faster than MEDP’s over the last 12 months.
MEDP's Profit vs Risk Rating (19) in the Miscellaneous Commercial Services industry is significantly better than the same rating for BRKR (100) in the Medical Specialties industry. This means that MEDP’s stock grew significantly faster than BRKR’s over the last 12 months.
MEDP's SMR Rating (11) in the Miscellaneous Commercial Services industry is significantly better than the same rating for BRKR (92) in the Medical Specialties industry. This means that MEDP’s stock grew significantly faster than BRKR’s over the last 12 months.
MEDP's Price Growth Rating (38) in the Miscellaneous Commercial Services industry is in the same range as BRKR (39) in the Medical Specialties industry. This means that MEDP’s stock grew similarly to BRKR’s over the last 12 months.
MEDP's P/E Growth Rating (54) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for BRKR (99) in the Medical Specialties industry. This means that MEDP’s stock grew somewhat faster than BRKR’s over the last 12 months.
| BRKR | MEDP | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 69% |
| Stochastic ODDS (%) | 1 day ago 81% | 1 day ago 64% |
| Momentum ODDS (%) | 1 day ago 76% | 1 day ago 77% |
| MACD ODDS (%) | 1 day ago 76% | 1 day ago 82% |
| TrendWeek ODDS (%) | 1 day ago 73% | 1 day ago 60% |
| TrendMonth ODDS (%) | 1 day ago 78% | 1 day ago 78% |
| Advances ODDS (%) | 3 days ago 69% | 5 days ago 75% |
| Declines ODDS (%) | 17 days ago 74% | 1 day ago 63% |
| BollingerBands ODDS (%) | 1 day ago 80% | 1 day ago 64% |
| Aroon ODDS (%) | N/A | 1 day ago 75% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BRKR’s FA Score shows that 1 FA rating(s) are green while MEDP’s FA Score has 2 green FA rating(s).
- BRKR’s FA Score: 1 green, 4 red.
- MEDP’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BRKR’s TA Score shows that 3 TA indicator(s) are bullish while MEDP’s TA Score has 5 bullish TA indicator(s).
- BRKR’s TA Score: 3 bullish, 5 bearish.
- MEDP’s TA Score: 5 bullish, 4 bearish.
Price Growth
BRKR (@Medical/Nursing Services) experienced а -0.90% price change this week, while MEDP (@Medical Specialties) price change was -2.57% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +0.04%. For the same industry, the average monthly price growth was -8.74%, and the average quarterly price growth was -9.59%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +2.12%. For the same industry, the average monthly price growth was -4.89%, and the average quarterly price growth was +48.45%.
Reported Earning Dates
BRKR is expected to report earnings on Nov 04, 2026.
MEDP is expected to report earnings on Feb 15, 2027.
Industries' Descriptions
@Medical/Nursing Services (+0.04% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (+2.12% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
BRKR and
Correlation & Price change
A.I.dvisor indicates that over the last year, BRKR has been closely correlated with A. These tickers have moved in lockstep 78% of the time. This A.I.-generated data suggests there is a high statistical probability that if BRKR jumps, then A could also see price increases.
| Ticker / NAME | Correlation To BRKR | 1D Price Change % | ||
|---|---|---|---|---|
| BRKR | 100% | -7.95% | ||
| A - BRKR | 78% Closely correlated | -3.47% | ||
| MTD - BRKR | 75% Closely correlated | -2.55% | ||
| WAT - BRKR | 68% Closely correlated | -3.61% | ||
| RVTY - BRKR | 68% Closely correlated | -5.30% | ||
| TMO - BRKR | 66% Loosely correlated | -1.72% | ||
More | ||||
MEDP and
Correlation & Price change
A.I.dvisor indicates that over the last year, MEDP has been loosely correlated with TMO. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if MEDP jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To MEDP | 1D Price Change % | ||
|---|---|---|---|---|
| MEDP | 100% | -3.77% | ||
| TMO - MEDP | 61% Loosely correlated | -1.72% | ||
| CRL - MEDP | 57% Loosely correlated | -4.44% | ||
| A - MEDP | 44% Loosely correlated | -3.47% | ||
| RVTY - MEDP | 44% Loosely correlated | -5.30% | ||
| BRKR - MEDP | 43% Loosely correlated | -7.95% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IMTG | 47.53 | N/A | N/A |
| Invesco Agency MBS ETF (IMTG) | |||
| EQAL | 59.17 | -0.47 | -0.79% |
| Invesco Russell 1000 Equal Weight ETF (EQAL) | |||
| NIHI | 50.35 | -0.42 | -0.83% |
| NEOS MSCI EAFE High Income ETF (NIHI) | |||
| EPRF | 15.45 | -0.14 | -0.87% |
| Innovator S&P Investment Grade Preferred ETF (EPRF) | |||
| AVDV | 105.11 | -1.72 | -1.61% |
| Avantis International Small Cap Value ETF (AVDV) | |||